Page 21 - Latest Updates on Trump tariffs

India may import US corn for ethanol production as trade talks advance

New Delhi seeks removal of penal tariffs on Russian oil purchases as Washington pushes soybean and corn sales, with both sides aiming to seal a trade pact by fall

Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit

Reforms to boost growth, but tariff suspense a risk, says FinMin

Finance ministry warns tariff risks could hit jobs and consumption, while GST rationalisation and reforms are seen as key to sustaining India's growth amid global uncertainties

Trump's new tariffs shake Asian economies still reeling from trade war

On Thursday, Trump announced another round of tariffs, which would go into effect on Oct 1, applying import duties ranging from 25 percent to 100 percent on pharmaceuticals, heavy trucks, etc

Nifty Pharma declines 2% after Donald Trump's 100% tariff on branded drugs

The index tracking domestic pharmaceutical stocks hit a low of 21,390 and then recouped some losses to end at 21,507

EU gears up to open 20 anti-dumping probes against Chinese products

The EU is preparing 20 anti-dumping investigations against China to protect European industries from cheap imports and overcapacity in Chinese manufacturing

Stock market crash today: Trump tariffs, FII selling drag Sensex 733 pts down, Nifty near 24,650

Sensex today | Stock Market crash highlights, Sept 26: In the broader markets, the Nifty MidCap index declined 2.05 per cent and the Nifty SmallCap index eased 2.2 per cent

Trump's tariff threat spotlights US factory plans of pharma firms

Merck & Co., Novo Nordisk A/S and Eli Lilly & Co. are among firms that have started US builds since 2023, with construction sites in Delaware, North Carolina and Texas

Carysil stock price dips 10% on Trump's 50% tariff; gives clarification

Carysil stock, however, pared part of its losses after the company issued a clarification. Around 1:45 PM, the stock was trading 5.12 per cent lower at ₹806.40.

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Asia stocks slide as Trump slaps new pharma tariffs, Fed cut bets recede

Shares of pharmaceutical companies across Asia tumbled in the aftermath, with Japan's Topix pharmaceutical index last down 1.2 per cent, while Hong Kong-listed innovative drug index fell 2 per cent

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Trump announces 100% tariff on pharma imports; duties on trucks, furniture

Trump said the new tariffs would not apply to companies that are actively building pharmaceutical manufacturing facilities in the US

Trump hosts Pak PM Shehbaz Sharif, Asim Munir amid strained India ties

Donald Trump hosted Pakistan PM Shehbaz Sharif at the White House, marking a thaw in US-Pakistan ties as India-US relations remain tense over tariffs and Russian oil imports

Robotics, medical gear, industrial machinery under Trump's new tariff push

The Trump administration has launched trade probes on robotics, industrial machines, and medical devices, paving the way for possible tariffs to boost US manufacturing

US acknowledges 'turbulence' with India but maintains positive trajectory

The current tensions centre primarily on trade disputes, with the Trump administration imposing additional tariffs on India over various commercial issues

China urges its companies to avoid taking domestic price wars to US

Wang said China and the US have reached a series of important consensus results after several rounds of economic and trade consultations

China ends developing-nation status to strengthen WTO amid Trump tariffs

China has said it would no longer seek the special treatment given to developing countries in World Trade Organisation agreements a change long demanded by the United States. Commerce Ministry officials on Wednesday said the move was an attempt to boost the global trading system at a time when it is under threat from tariff wars and protectionist moves by individual countries to restrict imports. They did not mention the United States by name or President Donald Trump's imposition of tariffs on many other countries this year, including China. The US has long argued China should give up the developing-country status because it is the world's second-largest economy. The advantages of that designation at the WTO include lower requirements to open their markets to imports and longer transition periods to implement such market-opening steps. The WTO provides a forum for global trade talks and enforces agreements but has become less effective, prompting calls for reform. The head of th

EXIM Bank boosts credit to exporters hit by tariffs, eyes Africa expansion

EXIM Bank is also offering more shorter-tenure credit and credit against future receivables to address exporters' immediate working capital needs

Rubio defends India-US bond, but warns tariffs signal stance on Russia war

Rubio made the comments in an interview with Good Morning America, stating that Trump's additional tariffs on India were part of actions taken against Russia for its war on Ukraine